Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ACACB | O00763 | 10/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 3/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PI4KA | P42356 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1547755 | 0.81 | ESR1 (0.45) | ALDH1A1ACACBESR1ESR2ACACA | |
| SCHEMBL1547590 | 0.79 | MAPT (0.47) | ALDH1A1ACACBESR1ESR2ACACA | |
| SCHEMBL2645473 | 0.79 | DAO (0.39) | ACACBESR1ESR2PIK3CDPIK3CA | |
| SCHEMBL30945175 | 0.79 | DAO (0.39) | ACACBESR1ESR2PIK3CDPIK3CA | |
| SCHEMBL6938238 | 0.77 | ALDH1A1 (0.50) | ALDH1A1ACACBPDE10ACHRNA7PIK3CD | |
| SCHEMBL30521521 | 0.76 | ACACB (0.47) | ALDH1A1ACACBPDE10ACHRNA7PIK3CD | |
| SCHEMBL21831271 | 0.76 | ACACB (0.47) | ALDH1A1ACACBPDE10ACHRNA7PIK3CD | |
| SCHEMBL10154319 | 0.76 | ESR1 (0.42) | ESR1ESR2GABRPGABRDGABRA1 | |
| SCHEMBL177831 | 0.76 | — | — | |
| SCHEMBL31435885 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115563-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC | 2025-04-10 | — | — | US | disclosed |
| EP-3704098-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-112154142-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20230144871-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2023-05-11 | — | — | US | disclosed |
| US-20210113532-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2021-04-22 | — | — | US | disclosed |
| EP-3778575-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2021-02-17 | — | — | EP | disclosed |
| CN-112154142-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2020-12-29 | — | — | CN | disclosed |
| US-10864196-B2 | Modulators of the integrated stress pathway | CALICO LIFE SCIENCES, LLC (US) | 2020-12-15 | — | — | US | disclosed |
| US-20200361881-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2020-11-19 | — | — | US | disclosed |
| EP-3704098-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2020-09-09 | — | — | EP | disclosed |
| CN-103554095-A | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome | ABBVIE INC | 2014-02-05 | — | — | CN | disclosed |
| US-8592629-B2 | Sulfonamide derivatives as Nav 1.7 inhibitors | PFIZER LIMITED (GB) | 2013-11-26 | — | — | US | disclosed |
| EP-2593432-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007861-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012007861-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010183-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010183-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010183-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| CN-101484433-A | Novel acetyl-coA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome | ABBOTT LAB (US) | 2009-07-15 | — | — | CN | disclosed |
| US-20070225332-A1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBVIE INC. | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144871-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ALDH1A1 3433/4885ACACB 560/4885PDE10A 3043/4885 |
| US-20210113532-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ALDH1A1 3433/4885ACACB 560/4885PDE10A 3043/4885 |
| US-20200361881-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ALDH1A1 3433/4885ACACB 560/4885PDE10A 3043/4885 |
| US-20120010183-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | ALDH1A1 1098/4885ACACB 4620/4885PDE10A 1045/4885 |
| US-10864196-B2 | Modulators of the integrated stress pathway | ATF4, ATF1, DDIT3 | ALDH1A1 3433/4885ACACB 560/4885PDE10A 3043/4885 |
| US-20250115563-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ALDH1A1 3433/4885ACACB 560/4885PDE10A 3043/4885 |
| US-20070225332-A1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ACACA, ACACB, ACAT1 | ALDH1A1 330/4885ACACB 2/4885PDE10A 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.